ABSTRACT

here was no specific vaccine or successful treatment for this rapidly spreading and lifethreatening viral respiratory infection in December of last year when COVID-19 emerged. Clinical trials have been planned and are underway to examine whether drugs used for influenza, HIV and other viruses, as well as antihelmintics (ivermectin) and antimalarials (chloroquine, hydroxychloroquine) that demonstrate in vitro antiviral activity, are successful and safe for Covid-19. No compelling evidence exists so far that these antiviral and anti parasitic drugs are of some interest to Covid-19. Notwithstanding the absence of clinical efficacy evidence, these medications are commonly used for prophylaxis and treatment of this viral infection outside of clinical trials (off label). This practice has been termed as offlabel usage and is legal provided that the same has been approved by national laws and regulations. In conclusion, the COVID-19 pandemic is a global issue and needs unparalleled global solutions, as we will not allow people to die from complications related to the disease. Keywords: Antihelmintics, Antimalarials, Anti parasitic, COVID-19, Prophylaxis
Publication date: 01/11/2021

https://ijbpas.com/pdf/2021/November/MS_IJBPAS_2021_5724.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.11.5724